National Cancer Institute

News National Cancer Institute

• Drug shown to reverse radioiodine resistance in some advanced thyroid cancers

  The experimental drug selumetinib may allow some patients with advanced thyroid cancer to overcome resistance to radioiodine (RAI), the most effective therapy for the disease, according to new research from Memorial Sloan-Kettering Cancer Center. Published in the issue of the New England Journal of more

• Horizon Discovery Announces Collaboration with the National Cancer Institute and the National Human Genome Research Institute

  Horizon Discovery announced it has entered into a three year Technology Access Agreement with the National Cancer Institute (NCI) and the National Human Genome Research Institute (NHGRI), both divisions of the National Institutes of Health. The focus of the agreement is to enable the NCI and NHGRI t more

• Bavarian Nordic Obtains Rights to New Cancer Vaccine Product Candidates

  Bavarian Nordic A/S announced that its BN ImmunoTherapeutics subsidiary has entered into an expanded strategic partnership with the National Cancer Institute (NCI). Under the licensing and Cooperative Research and Development Agreements (CRADA), the NCI and Bavarian Nordic will jointly develop new o more

Publications National Cancer Institute

• Inducers of Hypoxic Response: Marine Sesquiterpene Quinones Activate HIF-1

  The hypoxia-inducible factor-1 (HIF-1) transcription factor regulates cellular oxygen homeostasis. Agents that activate HIF-1 and downstream HIF targets represent potential drug leads for the prevention and/or treatment of ischemic disorders. In a search for small-molecule HIF-1 activators, 1936 mar more

• Animal Models of Human Prostate Cancer: The Consensus Report of the New York Meeting of the Mouse Models of Human Cancers Consortium Prostate Pathology Committee

  Animal models, particularly mouse models, play a central role in the study of the etiology, prevention, and treatment of human prostate cancer. While tissue culture models are extremely useful in understanding the biology of prostate cancer, they cannot recapitulate the complex cellular interactions more

• Organometallic Iridium(III) Anticancer Complexes with New Mechanisms of Action: NCI-60 Screening, Mitochondrial Targeting, and Apoptosis

  Platinum complexes related to cisplatin, cis-[PtCl2(NH3)2], are successful anticancer drugs; however, other transition metal complexes offer potential for combating cisplatin resistance, decreasing side effects, and widening the spectrum of activity. Organometallic half-sandwich iridium (IrIII) comp more

Market studies National Cancer Institute

• Cancer Diagnostic Testing World Markets

  Cancer testing is one of the most important growth opportunities for the next three to five years in the diagnostics segment. The National Cancer Institute estimates that about ten million Americans have or have had some form of cancer. Overall costs of the disease are $126 billion annually. Pharmac more

• Cancer Supportive Care Products Market to 2016 - Market is Expected to Decline after 2014 Due to Generic Erosion and Entry of Biosimilars

  GBI Research, the leading business intelligence provider, has released its latest research, “Cancer Supportive Care Products Market to 2016 – Market is Expected to Decline after 2014 Due to Generic Erosion and Entry of Biosimilars”, which provides insights into the cancer supportive care products ma more

• Leading Anti-Cancer Drugs: World Market Prospects 2011-2021

  What will this decade hold for leading anti-cancer drugs and that therapeutic market? Our new report shows you anti-cancer drug revenue forecasts for 2011 to 2021. We provide research, data and opinions to benefit your work now. What revenues will cancer treatment markets generate from 2011 to 2021 more

Websites National Cancer Institute